pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Lead Candidate · news · pharmadog
← back to Lead Candidate
News mentioning Lead Candidate
103
stories
10h
nChroma halves workforce, BioXcel lets execs go
biospace
21h
9 biotechs will cut at least half their California workforces
biospace
21h
Ramping up: 3 biotechs growing their workforce after series C raises
biospace
2d
Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo
biospace
2d
Kyntra axes mid-stage ADC, adding to years of stumbles
fiercebiotech
2d
Lilly signs $5.9B deal with Stipple to unlock oncology targets
fiercebiotech
3d
Sellas marks 9-month survival benefit in late-stage leukemia vaccine study
fiercebiotech
3d
J&J bets $2.2B on Ollin’s vision loss drug
biopharma dive
3d
J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial
biospace
3d
Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer work
biospace
3d
J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
fiercebiotech
6d
Marrow extracts $120M series B to advance preclinical blood disease therapy
fiercebiotech
7d
Windward prices $175M IPO to advance China-licensed lung drugs
biopharma dive
7d
Chutes & Ladders—Bristol Myers' research chief out amid R&D reorganization
fiercebiotech
7d
Biopharma layoffs rise YOY in October but sharply trend down for 2026
biospace
8d
PepGen shares almost double as DM1 oligonucleotide achieves ‘best in class’ splicing
biospace
17d
Tiziana touts multiple sclerosis win at lower dose as high dose misses mark
biospace
17d
Significant stock movers of October: Biohaven climbs, ArriVent dives
biospace
20d
New biotech Setara forms with $90M to take on Jazz’s bonus rare disease programs
biospace
20d
Molecular Partners to lay off up to 44% of workforce in radiotherapy pivot
fiercebiotech
23d
After 2 patient deaths and cell therapy durability concerns, Artiva cuts 94% of workforce
biospace
28d
Rebranded NodThera plans IPO to fund NLRP3 inhibitor’s push toward approval
fiercebiotech
29d
STAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approved
stat
29d
The 6 biggest crossover rounds in biopharma history
biospace
Oct 20, 26
Rapport ekes out bipolar mania win as lead asset ‘just hits’ in mid-stage trial
biospace
Oct 20, 26
Lycia aims for $228M IPO to generate data on food allergy rival to Xolair
fiercebiotech
Oct 19, 26
Merck KGaA makes noise in hematology with $1.1B Silence buy
biospace
Oct 14, 26
Why OMass’ $310M series C marks ‘fantastic milestone’ on journey to become ‘Britain’s Big Biotech’
fiercebiotech
Oct 12, 26
Parkinson’s cell therapy developer files to go public
biopharma dive
Oct 11, 26
The 2026 Biotech Graveyard
fiercebiotech
← prev
page 1 of 4
next →